Taysha Gene Therapies (TSHA) Income from Continuing Operations (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Income from Continuing Operations of 98114000.0 for Q1 2026, down 285.64% sequentially from 25442000.0 in Q4 2025, and down 243.13% YoY from 68549863.56 in Q1 2025.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Income from Continuing Operations for 7 years, with the latest figure at 98114000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 243.13% year-over-year to 98114000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 236710000.0 (down 76.18% YoY) and the FY2025 annual result came in at 182951000.0, up 7.9% from the prior year.
- Income from Continuing Operations fell to 98114000.0 in Q1 2026 per TSHA's latest filing, from 25442000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 15658000.0 in Q4 2023 and troughed at 98114000.0 in Q1 2026.
- A 5-year average of 41216882.35 and a median of 34116000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations surged 72.04% in 2023, then slumped 243.13% in 2026.
- Over 5 years, Income from Continuing Operations stood at 56006000.0 in 2022, then soared by 72.04% to 15658000.0 in 2023, then sank by 49.66% to 23434000.0 in 2024, then dropped by 8.57% to 25442000.0 in 2025, then sank by 285.64% to 98114000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 98114000.0, 25442000.0, and 61988000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | -45.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.03 Mn |
| Mar 31, 2026 | -40.91 Mn |
| Dec 31, 2025 | -25.44 Mn |
| Sep 30, 2025 | -30.87 Mn |
| Jun 30, 2025 | -24.91 Mn |
| Mar 31, 2025 | -20.11 Mn |
| Dec 31, 2024 | -18.25 Mn |
| Sep 30, 2024 | -23.82 Mn |
| Jun 30, 2024 | -19.89 Mn |
| Mar 31, 2024 | -22.67 Mn |
| Dec 31, 2023 | -15.04 Mn |
| Sep 30, 2023 | -16.61 Mn |
| Jun 30, 2023 | -24.60 Mn |
| Mar 31, 2023 | -17.61 Mn |
| Dec 31, 2022 | -55.07 Mn |
| Sep 30, 2022 | -26.53 Mn |
| Jun 30, 2022 | -34.09 Mn |
| Mar 31, 2022 | -50.31 Mn |
| Dec 31, 2021 | -50.39 Mn |
| Sep 30, 2021 | -51.19 Mn |